To foray into the lucrative obesity market, Merck MRK announced that it is in-licensing global rights to an investigational ...

Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines. Click here to check out my ...

The big pharma is paying Hansoh $112 million upfront to place its bet on oral GLP-1 receptor agonist HS-1035, with another $1 ...

The server maker has been on a roller coaster, getting caught up in the excitement about artificial intelligence which helped shares lift to a March high, but worries about accounting dragged them ...

RAHWAY, NJ, USA I 18, 2024 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical ...

Merck & Co (MSD) has entered an exclusive global licence agreement with China-based Hansoh Pharma for a preclinical oral ...

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...

MERCK snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as US$2 billion. Read ...

By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals' dominance in the GLP-1 ...

In other news of note, Merck (MRK) joins the weight-loss drug race. Merck and China’s Hansoh Pharma (OTCPK:HNSPF) announced a ...

( MENAFN - Baystreet) Merck (NYSE:MRK) on Wednesday said it has snagged the rights to an experimental weight loss pill from ...